Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

NCT00087607 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

385

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Ribavirin
DRUG: Peginterferon alfa-2b (PEG-Intron)
DRUG: Ribavirin
DRUG: Peginterferon alfa-2a [Pegasys]

Sponsor

Hoffmann-La Roche